Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 7/20 | 0.61 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.58 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 11/20 | 0.55 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501027 | 0.85 | PDPK1 (0.62) | PDPK1IKBKEALKTNIK | |
| SCHEMBL12501063 | 0.82 | PDPK1 (0.69) | PDPK1IKBKETBK1ALKTNIK | |
| SCHEMBL26175331 | 0.78 | PDPK1 (0.52) | PDPK1ALK | |
| SCHEMBL26175363 | 0.77 | ALK (0.57) | PDPK1ALKTNIK | |
| SCHEMBL18534314 | 0.77 | PDPK1 (0.65) | PDPK1IKBKETBK1ALKTNIK | |
| SCHEMBL15397147 | 0.77 | ALK (0.49) | PDPK1ALK | |
| SCHEMBL2753672 | 0.76 | ALK (0.74) | PDPK1ALKTNIK | |
| SCHEMBL12501057 | 0.76 | PDPK1 (1.00) | PDPK1IKBKETBK1ALKTNIK | |
| SCHEMBL18098840 | 0.76 | PDPK1 (0.66) | PDPK1IKBKETBK1ALK | |
| SCHEMBL12501111 | 0.75 | PDPK1 (0.48) | PDPK1TBK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133074-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2017-02-22 | — | — | EP | claimed |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | claimed |
| EP-2746281-A2 | 7-azaindole derivatives | Merck Patent GmbH (DE) | 2014-06-25 | — | — | EP | claimed |
| EP-2670748-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2013-12-11 | — | — | EP | claimed |
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | claimed |
| WO-2012104007-A2 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-08-09 | — | — | WO | claimed |
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | claimed |
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| EP-3133074-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-8981101-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| US-8981101-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| EP-2746281-A2 | 7-azaindole derivatives | Merck Patent GmbH (DE) | 2014-06-25 | — | — | EP | disclosed |
| EP-2746281-A2 | 7-azaindole derivatives | Merck Patent GmbH (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | PDK1, PDK2, PDK3 | PDPK1 12/4885IKBKE 1071/4885TBK1 2204/4885 |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | PDK1, PDK2, PDK3 | PDPK1 12/4885IKBKE 1100/4885TBK1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.